Novartis gains U.S. approval for delayed MS drug

ZURICH (Reuters) - Novartis's Sandoz division has won U.S. approval for a larger dosage of its Glatopa drug for multiple sclerosis (MS) patients, ending a costly delay that allowed rival generics makers to beat it to market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news